Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Largo Madonna Delle Grazie, 80128, Naples, Italy.
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127, Palermo, Italy.
Reprod Sci. 2024 Nov;31(11):3247-3256. doi: 10.1007/s43032-024-01707-4. Epub 2024 Sep 27.
Women with endometriosis were deemed more prone to COVID-19 infection in some reports. Considering that endometriosis-related aberrant immune response, understanding how COVID-19 vaccination influences its clinical status is crucial. The aim of this meta-analysis was the evaluate the susceptibility to COVID-19 infection and modifications of symptoms following COVID-19 vaccination in women with endometriosis. Electronic searches on EMBASE, MEDLINE, Scopus, Cochrane at CENTRAL, Scielo.br, LILACS and other databases were searched from inception to March 2024. Studies were eligible if they analyzed the incidence of infection in endometriosis women or the changes in symptoms after two doses of COVID-19 vaccine and had a control group. Four studies (2249 women) were included. No increased susceptibility to COVID-19 infection due to presence or absence of endometriosis was retrievable (risk ratio (RR) 1.42 [95% CI 0.88 to 2.27]; I = 33%). Patients with endometriosis did not experience an overall worsening of symptomatology relative to controls (RR 1.58 [95% CI 0.67 to 3.75]; I = 94%). An increase in the risk of dysmenorrhea worsening was noted (RR 1.88 [95% CI 1.11 to 3.17]; I = 63%). No other differences regarding menstrual flow (RR 1.25 [95% CI 0.70 to 2.23]; I = 78%), intermenstrual bleeding (RR 1.14 [95% CI 0.83 to 1.56]; I = 39%) and pelvic pain (RR 2.55 [95% CI 0.65 to 10.05]; I = 80%) compared to controls was retrievable. Therefore, mRNA vaccines do not seem to lead to worsening of symptomatology in endometriotic women. However, a slight temporary increase in dysmenorrhea may be present. Moreover, endometriosis does not seem to increase the risk of contracting COVID-19.
一些报告认为，子宫内膜异位症患者更容易感染 COVID-19。考虑到子宫内膜异位症相关的异常免疫反应，了解 COVID-19 疫苗接种如何影响其临床状况至关重要。本荟萃分析的目的是评估子宫内膜异位症患者感染 COVID-19 的易感性以及 COVID-19 疫苗接种后症状的变化。从开始到 2024 年 3 月，在 EMBASE、MEDLINE、Scopus、Cochrane 中心、Scielo.br、LILACS 和其他数据库上进行了电子检索。如果研究分析了子宫内膜异位症女性的感染发生率或 COVID-19 疫苗两剂接种后症状的变化，并设有对照组，则符合纳入标准。纳入了四项研究（2249 名女性）。没有发现子宫内膜异位症的存在或不存在会导致感染 COVID-19 的易感性增加（风险比（RR）1.42 [95% CI 0.88 至 2.27]；I = 33%）。与对照组相比，子宫内膜异位症患者的症状总体没有恶化（RR 1.58 [95% CI 0.67 至 3.75]；I = 94%）。注意到痛经恶化的风险增加（RR 1.88 [95% CI 1.11 至 3.17]；I = 63%）。与对照组相比，月经流量（RR 1.25 [95% CI 0.70 至 2.23]；I = 78%）、月经间期出血（RR 1.14 [95% CI 0.83 至 1.56]；I = 39%）和盆腔疼痛（RR 2.55 [95% CI 0.65 至 10.05]；I = 80%）没有差异。因此，mRNA 疫苗似乎不会导致子宫内膜异位症女性的症状恶化。然而，可能会出现轻微的暂时性痛经加重。此外，子宫内膜异位症似乎不会增加感染 COVID-19 的风险。
